| Bioactivity | Elsiglutide (ZP1846) is a GLP-2 analogue, an orally active and selective GLP-2 receptor agonist, increases cell proliferation and reduces apoptosis in the intestine. Elsiglutide improves Lapatinib (HY-50898)-induced diarrhoea in rat model[1][2]. |
| In Vivo | Elsiglutide (500 mg/kg; p.o.; once daily; 4 times per week for 4 weeks) reduces the most severe diarrhoea seen from Lapatinib (500 mg/kg; p.o.) in rat model[1]. Animal Model: |
| Name | Elsiglutide |
| CAS | 914009-84-0 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mayo BJ, et al. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats. Cancer Chemother Pharmacol. 2020 Apr;85(4):793-803. [2]. Mayo B, et al. The new selective glp-2 receptor agonist, elsiglutide, improves irinotecan-induced diarrhoea and mucositis in the rat. Asia Pacific Journal of Clinical Oncology, 2014, vol.10, iss.Suppl. 8, pp.134-134. |